ASH 2024: The new CEO of Innate Pharma on taking the job and the company's work on antibodies, engagers, and ADCs
Jonathan Dickinson describes what appealed to him about Innate. He discusses the pipeline, including ASH data from the lead program Lacutamab and an NK engager program Sanofi is partnered on.